← All trials
NCT01285219
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2006
- Primary completion
- May 1, 2007
- Completion date
- Dec 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 337
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Fudan UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Central South UniversityCollaborator
- Capital Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Sichuan UniversityCollaborator
- Zhejiang UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Peking UniversityCollaborator
- Dalian Medical UniversityCollaborator
- China Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.